Teligent Shares Outstanding 2012-2021 | TLGT
Teligent shares outstanding from 2012 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Teligent Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2020 | 8 |
| 2019 | 5 |
| 2018 | 5 |
| 2017 | 5 |
| 2016 | 5 |
| 2015 | 7 |
| 2014 | 6 |
| 2013 | 4 |
| 2012 | 4 |
| 2011 | 4 |
|
Teligent Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2021-06-30 | 93 |
| 2021-03-31 | 77 |
| 2020-12-31 | 8 |
| 2020-09-30 | 6 |
| 2020-06-30 | 6 |
| 2020-03-31 | 5 |
| 2019-12-31 | 5 |
| 2019-09-30 | 5 |
| 2019-06-30 | 5 |
| 2019-03-31 | 5 |
| 2018-12-31 | 5 |
| 2018-09-30 | 5 |
| 2018-06-30 | 5 |
| 2018-03-31 | 5 |
| 2017-12-31 | 5 |
| 2017-09-30 | 5 |
| 2017-06-30 | 5 |
| 2017-03-31 | 5 |
| 2016-12-31 | 5 |
| 2016-09-30 | 5 |
| 2016-06-30 | 5 |
| 2016-03-31 | 5 |
| 2015-12-31 | 7 |
| 2015-09-30 | 5 |
| 2015-06-30 | 7 |
| 2015-03-31 | 7 |
| 2014-12-31 | 6 |
| 2014-09-30 | 5 |
| 2014-06-30 | 5 |
| 2014-03-31 | 5 |
| 2013-12-31 | 4 |
| 2013-09-30 | 4 |
| 2013-06-30 | 4 |
| 2013-03-31 | 4 |
| 2012-12-31 | 4 |
| 2012-09-30 | 4 |
| 2012-06-30 | 4 |
| 2012-03-31 | 4 |
| 2011-12-31 | 4 |
| 2011-09-30 | 4 |
| 2011-06-30 | 4 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |